ReadCoor, Inc.

Second Injunction Issued Against CosMx PLEASANTON, Calif., Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in all 17 countries of the UPC. Eric S. Whitaker, Chief Legal Officer for 10x Genomics, said: "Since the formation of 10x, our unwavering commitment has been to drive innovation to push science forward. We have made massive investments in cutting edge research and development resulting in revolutionary products transforming the world's understanding of health and disease. The entire purpose of patent systems around the world is to protect such innovations and encourage such investments. We will be steadfast in protecting the inventions that scientists have worked so hard to create, as innovation is what fuels and funds the development of future 10x technologies that benefit researchers – and ultimately patients." The injunction on the EP 782 patent requires that NanoString stop selling or providing services using the CosMx SMI instruments as well as CosMx reagents for RNA detection in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia and Sweden. 10x Genomics' acquisitions of ReadCoor and Cartana in 2020 accelerated its technology development of the Xenium in situ platform and provided 10x with access to key inventions, including what became the EP 782 patent, from the earliest pioneers of in situ analysis. This patent relates to the initial discoveries of critical and foundational technical features for in situ analysis, which underpin 10x's Xenium platform, a high performance system combining state-of-the-art instrumentation, curated and customizable gene panels and robust software to deliver best-in-class sensitivity, specificity and throughput. "A patent holder must meet a very high standard to win a preliminary injunction," added Whitaker. "Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope. In total, three courts have analyzed hundreds of pages of arguments made by NanoString and have rejected NanoString's repeated claims that it does not infringe 10x patents, that the patents are invalid or that NanoString's claims to a license have merit. Although we welcome legitimate competition on the merits, competition based on our own innovations must stop." The ruling of the UPC is subject to appeal. The preliminary injunction takes immediate effect today. The full opinions of the Unified Patent Court will be posted here when available: 10xgen.com/munich-spatial-news. Related Litigation In a separate case before the UPC, 10x also requested a preliminary injunction against the CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection for infringing European Patent 2 794 928 B1 ("the EP 928 patent," docket No 459996/2023), which is in effect in France and the Netherlands in addition to Germany. The UPC held a hearing on this request today and announced that it expected to issue a decision on October 10, 2023. In the United States, 10x filed suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString's GeoMx Digital Spatial Profiler and associated instruments, reagents and services infringe: (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. Trial is scheduled for November 2023. On September 7, the Court issued summary judgment in favor of 10x and dismissed NanoString's defenses relating to invalidity for indefiniteness. 10x has stated that it intends to seek more than $30 million in damages for sales prior to trial; this amount can be trebled in the event that the jury finds NanoString's infringement willful. 10x also intends to seek an injunction against sales of GeoMx as well as ongoing damages. 10x filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe multiple patents in the same patent family as EP 782 and EP 928, the patents NanoString has been enjoined from infringing by the UPC and German courts. The patents asserted in the second U.S. suit against NanoString include (a) U.S. Patent No. 10,227,639; (b) U.S. Patent No. 11,021,737; (c) U.S. Patent No. 11,293,051; (d) U.S. Patent No. 11,293,052; (e) U.S. Patent No. 11,293,054 and (f) U.S. Patent No. 11,542,554. Trial is scheduled for September 2024. As previously announced, in February 2023, a five judge panel from the German Federal Patent Court, which included technical experts, issued a preliminary opinion finding the asserted claims of the EP 928 patent valid (docket no. 3 Ni 20/22). An oral hearing is scheduled for May 7, 2024. On May 17, a three judge panel of the Munich Regional Court found that the EP 928 patent was infringed and issued an injunction that requires NanoString to stop selling and supplying CosMx SMI instruments as well as CosMx reagents for RNA detection in Germany (docket No. 7 O 2693/22). NanoString appealed this decision to the Higher Regional Court Munich (docket No. 6 U 2360/23 e). A decision is not expected before late 2024. Prior to today's preliminary injunction ruling on the EP 782 patent, 10x filed two main actions before the UPC to obtain decisions on the merits regarding infringement of the EP 782 and EP 928 patents by NanoString selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection. Decisions on both main actions are expected for late 2024 (docket No 568963/2023 re EP 782; docket No 573637/2023 re EP 928). About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter). Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding litigation and remedies as well as possible outcomes of litigation. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable, or there may be changes in our litigation strategy. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website (), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: [email protected] Media: [email protected] SOURCE 10x Genomics, Inc.

Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissues Opens preorders for CytAssist, the company's first spatial instrument Shares new data on the company's Xenium In Situ Analyzer, expected to ship by year-end PLEASANTON, Calif., June 7, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla. The latest developments across 10x Genomics' leading Chromium and Visium platforms and the highly anticipated Xenium launch expected later this year showcase the company's leadership and innovation at the forefront of single-cell analysis, spatial biology, and in situ technology. "With major advances in each of our three platforms, we are executing to make 2022 the most exciting year of product launches in our history," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics. "As the only company with technologies that cover single cell, spatial and in situ analysis, we're in the best position to fuel researchers' discoveries and unlock new biological insights that will ultimately advance human health. We look forward to demonstrating the power of 10x Genomics' leading platforms, showcasing researchers' success with our technologies and highlighting our robust product pipeline at AGBT." In addition to the new developments announced today, 10x Genomics will host a workshop at AGBT on Thursday, June 9, at noon Eastern to share the latest data across its three platforms, including Xenium. Chromium As part of the company's robust R&D pipeline, 10x Genomics is driving innovation to enable broad adoption of the Chromium single-cell platform by increasing access to more sample types, removing bottlenecks, and giving researchers a more flexible and streamlined workflow. 10x Genomics today announced the compatibility of its recently launched Fixed RNA Profiling Kit to enable single-cell transcriptomics on dissociated formalin-fixed, paraffin-embedded (FFPE) tissues. This groundbreaking capability enables single-cell analysis on preserved biobank samples for the first time ever. FFPE tissues are ideal for translational and clinical research, yet have remained inaccessible for single-cell analysis until now. "Our Chromium platform has fueled thousands of discoveries and helped profile more than 5 billion cells, accelerating the scientific community's understanding and mastery of biology," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "Yet, all of these insights have been generated in prospective studies leveraging fresh or fresh-frozen tissues. Now, for the first time ever, researchers can look retrospectively and analyze FFPE tissues at single-cell resolution and scale. By opening up the archives for single-cell analysis, we have the potential to truly transform the future of health and medicine." Both the Fixed RNA Profiling Kit and the previously announced Nuclei Isolation Kit, 10x Genomics' first sample preparation product, are now shipping. Visium 10x Genomics announced the launch and pre-order availability of two new products in its Visium portfolio, the leading spatial discovery platform: Visium CytAssist - The company's first spatial instrument, Visium CytAssist helps researchers bridge the world of histology and genomics and enables spatial profiling insights to be gained from an expanded range of FFPE samples. The compact, benchtop system simplifies sample processing by facilitating the transfer of analytes from tissue sections pre-mounted on standard glass slides to Visium slides. Visium for FFPE v2: Demonstrating its continued commitment to innovation and rapid advancements, 10x Genomics is launching the second version of its spatial FFPE workflow, less than one year after releasing the initial Visium for FFPE assay. Visium for FFPE v2 features several product advancements and workflow improvements, including the flexibility for larger capture areas and the ability to profile RNA and dozens of proteins simultaneously in the same FFPE tissue section at high spatial resolution. The v2 assay is expected to begin shipping later this month. "Spatial genomics takes single-cell characterization to the next dimension, and 10x Genomics is leading the way in spatial biology with several new launches that will help further researchers' understanding of health and disease," said Schnall-Levin. "We are excited about the breadth of our spatial analysis product roadmap, which will help further the capabilities of the Visium platform with new technologies focused on enabling more analytes, more samples, and greater resolution." Xenium Building on its leadership and innovation in single-cell and spatial analysis, 10x Genomics is planning to launch its Xenium platform for in situ analysis later this year. "In situ analysis that allows for true single-cell spatial resolution is the next frontier of biology, and we're incredibly excited to launch our Xenium platform later this year," said Schnall-Levin. "The initial launch is just the beginning for us. We have an extensive, multi-year product roadmap that will unlock the full capabilities of the Xenium platform and deliver on the promise and potential of in situ analysis." 10x Genomics developed the Xenium platform by uniting its internal development with its 2020 acquisitions of CartaNa and ReadCoor, which provided intellectual property, key technology advances, and deep talent and expertise in the emerging in situ field. To date, the company has more than 200 patents issued and pending in the in situ field, including key patents for features related to high throughput and high sensitivity. At launch, Xenium is expected to offer single-molecule RNA analysis at subcellular resolution and be compatible with both fresh frozen and FFPE tissues. In addition, 10x Genomics is developing Xenium to have the highest throughput of any instrument in its class. 10x Genomics expects to begin shipping the Xenium Analyzer by year-end. Posters 10x Genomics will present five posters during AGBT demonstrating the use of its platforms to generate novel biological insights. Poster #305, Session 1: Barcode Enabled Antigen Mapping (BEAM) enables next-generation systems immunology analysis of the post-COVID-19 immune landscape Presented by Sarah Taylor, Ph.D., Director of Applications Poster #502, Session 2: High sensitivity single cell RNA profiling of fixed cells via in situ RNA-templated ligation Presented by Andrew Kohlway, Ph.D., Senior Staff Scientist Poster #528, Session 2: Unlocking the power of scale with high-throughput multiomic single cell assays Presented by Dagmar Walter, Ph.D., Staff Scientist Poster #594, Session 2: A new spin on sample preparation: rapid, scalable isolation of nuclei for single cell genomics Presented by Mike Gibbons, Ph.D., Senior Scientist Poster #600, Session 2: Combining highly multiplexed protein and transcriptome-wide RNA expression to achieve spatially resolved multiomic characterization of the tumor microenvironment in FFPE tissues Presented by Marlon Stoeckius, Ph.D., Co-Director of R&D, Stockholm About 10x Genomics 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,700 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,350 issued patents and patent applications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project" "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding our business operations, financial performance and results of operations, including our expectations regarding 10x Genomics, Inc.'s product roadmap, as well as our ability to meet our anticipated cash needs for the foreseeable future. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, as the COVID-19 pandemic is continuously evolving, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website (), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: [email protected] Media: [email protected] SOURCE 10x Genomics, Inc.

Q4 2020 revenue growth of 49% over prior year PLEASANTON, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- 10X Genomics Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021. RecentHighlights Revenue was $298.8 million for the full year and $112.2 million for the fourth quarter of 2020, representing 22% and 49% increases over the corresponding periods of 2019 2,412 Chromium instruments sold as of December 31, 2020 More than 2,200 peer-reviewed publications based on data generated using 10x products Operations center in Singapore came online and began consumables manufacturing FourthQuarter2020FinancialResults Revenue was $112.2 million for the three months ended December 31, 2020, a 49% increase from $75.3 million for the three months ended December 31, 2019. This increase was primarily the result of increased consumables revenue driven by growth in the instrument installed base. Gross margin was 83% for the fourth quarter of 2020, as compared to 78% for the corresponding prior year period. The increase in gross margin was driven primarily by a smaller percentage of product sales being subject to royalties under ongoing litigation due to the transition to Next GEM products, partially offset by higher costs from newly introduced products. Operating expenses were $502.9 million for the fourth quarter of 2020, a 653% increase from $66.8 million for the three months ended December 31, 2019, and included $406.9 million of in-process research and development expense related to intellectual property purchased in connection with the acquisition of ReadCoor. Other drivers of the increase in operating expenses this quarter include increased personnel expenses, including stock-based compensation, and increased litigation expenses. Operating loss was $409.6 million for the fourth quarter of 2020, as compared to an operating loss of $8.1 million for the corresponding prior year period. This includes $14.3 million of stock-based compensation for the fourth quarter of 2020, as compared to $5.1 million for the fourth quarter of 2019. Net loss was $415.6 million for the fourth quarter of 2020, as compared to a net loss of $7.1 million for the corresponding prior year period. FullYear2020FinancialResults Revenue was $298.8 million for the year ended December 31, 2020, a 22% increase from $245.9 million for 2019. Gross margin was 80% for full year 2020, as compared to 75% for 2019. The increase in gross margin was driven primarily by a smaller percentage of product sales being subject to royalties under ongoing litigation due to the transition to Next GEM products, partially offset by higher costs from newly introduced products. Operating expenses were $774.5 million for full year 2020, as compared to $215.4 million for 2019, an increase of 260%. Operating expenses in 2020 included $447.5 million of in-process research and development expense related to intellectual property purchased in connection with the acquisitions of CartaNA and ReadCoor. Operating loss was $534.1 million for full year 2020, as compared to an operating loss of $30.6 million for 2019. This includes $48.6 million of stock-based compensation for full year 2020, as compared to $13.3 million for full year 2019. Net loss was $542.7 million for full year 2020, as compared to a net loss of $31.3 million for 2019. This includes $447.5 million of in-process research and development expense described above. Cash and cash equivalents were $663.6 million as of December 31, 2020, which include net proceeds of $482.2 million arising from the successfully completed follow-on stock offering in September 2020. 2021FinancialGuidance 10x Genomics expects full year 2021 revenue to be in the range of $480 million to $500 million, representing 61% to 67% growth over full year 2020 revenue. WebcastandConferenceCallInformation 10x Genomics will host a conference call to discuss the fourth quarter and full year 2020 financial results, business developments and outlook after market close on Wednesday, February 17, 2021 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at . The webcast will be archived and available for replay for at least 45 days after the event. About10xGenomics 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2019 based on publications and all of the top 20 global pharmaceutical companies by 2019 research and development spend, and have been cited in over 2,200 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 1,000 issued patents and patent applications. ForwardLookingStatements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding the company’s business operations, financial performance and results of operations as well as the company’s ability to meet its anticipated cash needs for the foreseeable future. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19 pandemic. Other risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, as the COVID-19 pandemic is unprecedented and continuously evolving, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward- looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. DisclosureInformation 10x Genomics uses filings with the Securities and Exchange Commission, its website ( ), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com 10xGenomics,Inc. CondensedConsolidatedStatementsofOperationsandComprehensiveLoss (Unaudited) (Inthousands,exceptshareandpersharedata) ThreeMonthsEndedDecember31, Twelve Months EndedDecember31, 2020 2019 2020 2019 Revenue $ 112,218 $ 75,289 $ 298,845 $ 245,893 Cost of revenue (1) 18,897 16,582 58,468 61,033 Gross profit 93,321 58,707 240,377 184,860 Operating expenses: Research and development (1) 39,704 27,889 123,375 83,097 In-process research and development 406,911 — 447,548 — Selling, general and administrative (1) 55,974 38,756 202,326 130,834 Accrued contingent liabilities 314 142 1,270 1,502 Total operating expenses 502,903 66,787 774,519 215,433 Loss from operations (409,582 ) (8,080 ) (534,142 ) (30,573 ) Other income (expense): Interest income 61 1,819 1,532 2,805 Interest expense (317 ) (992 ) (1,682 ) (3,079 ) Other income (expense), net 1,216 227 1,337 (186 ) Loss on extinguishment of debt — — (1,521 ) — Total other expense 960 1,054 (334 ) (460 ) Loss before provision for income taxes (408,622 ) (7,026 ) (534,476 ) (31,033 ) Provision for income taxes 6,950 108 8,255 218 Net loss $ (415,572 ) $ (7,134 ) $ (542,731 ) $ (31,251 ) Other comprehensive loss: Foreign currency translation adjustment 2 114 (4 ) (9 ) Comprehensive loss $ (415,570 ) $ (7,020 ) $ (542,735 ) $ (31,260 ) Net loss per share, basic and diluted $ (3.87 ) $ (0.07 ) $ (5.37 ) $ (0.80 ) Weighted-average shares used to compute net loss per share, basic and diluted 107,386,772 96,027,247 101,151,675 39,091,366 (1) Includes stock-based compensation expense as follows: ThreeMonthsEndedDecember31, Twelve Months Ended December31, (inthousands) 2020 2019 2020 2019 Cost of revenue $ 443 $ 154 $ 1,551 $ 325 Research and development 5,225 2,273 19,623 5,721 Selling, general and administrative 8,601 2,648 27,452 7,287 Total stock-based compensation expense $ 14,269 $ 5,075 $ 48,626 $ 13,333 10xGenomics,Inc. CondensedConsolidatedBalanceSheets (Unaudited) (Inthousands,exceptshareandpersharedata) December31, 2020 December 31, 2019 Current assets: Cash and cash equivalents $ 663,603 $ 424,166 Restricted cash 16,567 — Accounts receivable, net 51,208 33,371 Inventory 29,959 15,270 Prepaid expenses and other current assets 13,029 8,033 Total current assets 774,366 480,840 Property and equipment, net 72,840 48,821 Restricted cash 8,474 52,327 Operating lease right-of-use assets 46,983 — Other assets 26,678 23,935 Total assets $ 929,341 $ 605,923 Liabilitiesandstockholders’equity Current liabilities: Accrued contingent liabilities $ 44,173 $ — Accounts payable 4,709 13,028 Accrued compensation and related benefits 15,383 12,394 Accrued expenses and other current liabilities 43,453 24,448 Term loans, current portion — 9,882 Deferred revenue, current 4,472 3,297 Operating lease liabilities 5,936 — Total current liabilities 118,126 63,049 Term loans, noncurrent portion — 19,837 Accrued contingent liabilities — 68,658 Accrued license fee, noncurrent 11,171 16,251 Deferred rent, noncurrent — 16,120 Operating lease liabilities, noncurrent 57,042 — Other noncurrent liabilities 3,930 1,925 Total liabilities 190,269 185,840 Commitments and contingencies Stockholders' equity: Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of December 31, 2020 and December 31, 2019 — — Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 108,485,909 and 96,241,596 shares issued and outstanding as of December 31, 2020 and 2019 2 2 Additional paid-in capital 1,544,218 682,494 Accumulated deficit (805,098 ) (262,367 ) Accumulated other comprehensive loss (50 ) (46 ) Total stockholders’ equity 739,072 420,083 Total liabilities and stockholders’ equity $ 929,341 $ 605,923